MPS Pharmaa Ltd.
Snapshot View

2.00 ▼0%

16 January 2023, 04:01:00 PM

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.advikindia.com
Market Cap 3.82 Cr.
Enterprise Value(EV) 10.21 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) -0.17 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-09
Industry PE 32.90 Trailing Twelve Months Ending 2022-09
Book Value / Share 1.75 Trailing Twelve Months Ending 2022-09
Price to Book Value 1.14 Calculated using Price: 2.00
Dividend Yield 0.00 Period Ending 2022-03
No. of Shares Subscribed 1.91 Cr. 19,111,400 Shares
FaceValue 10
Company Profile
Advik Laboratories has been set up by V K Jain, a qualified production chemist with over 20 years experience in pharmaceutical products.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
1 Week
1 Month
+4.71%
3 Month
+9.89%
6 Month
+20.48%
1 Year
+50.38%
2 Year
+455.56%
5 Year
-70.24%
10 Year
-69.37%
9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 3.24 -4.03 -6.79 -48.30 -7.74 -12.28 -13.04 -71.73 -3.64
Return on Capital Employed (%) 8.13 0.59 -4.23 -33.90 -5.91 -7.76 -8.08 -36.90 -9.64
Return on Assets (%) 1.45 -2.01 -3.91 -29.85 -4.32 -6.79 -6.87 -31.87 -1.32

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 20 19 19 12 11 10 8 4 4 3
Non Curr. Liab. 4 3 2 1 1 1 1 1 0 0
Curr. Liab. 10 10 7 8 8 7 7 7 6 7
Minority Int.
Equity & Liab. 35 32 29 21 19 18 16 11 10 10
Non Curr. Assets 16 15 15 14 13 12 11 9 8 8
Curr. Assets 19 17 14 7 7 5 5 2 2 2
Misc. Exp. not W/O
Total Assets 35 32 29 21 19 18 16 11 10 10

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 30 12 1 3 4 1 0 0
Other Income 0 0 0 0 0 0 0
Total Income 30 12 1 3 4 1 0 0 0 0
Total Expenditure -27 -11 -2 -10 -5 -2 -1 -4 -1 -1
PBIDT 3 1 0 -7 0 -1 -1 -4 0 -1
Interest -1 -1 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1 0
Taxation -1 0 0 0 0 0 0 0 1 1
Exceptional Items
PAT 0 -1 -1 -7 -1 -1 -1 -4 0 0
Adjusted EPS 0 0 -1 -4 0 -1 -1 -2 0 0

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 5 2 1 0 0 1 0 -1 -4
Cash Fr. Inv. 0 -6 0 0 1 0 0 0 2 0
Cash Fr. Finan. 0 2 -2 -1 -1 0 0 -1 4
Net Change 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0 0 0

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 35.89 35.89 35.89 35.89 35.89 35.89 35.89 35.89 35.89
Public 64.11 64.11 64.11 64.11 64.11 64.11 64.11 64.11 64.11
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 71.16 16.04 16.04 16.04 16.04 16.04 16.04 16.04 16.04

Announcements View Details >>

Mon, 23 Jan 2023
Board Meeting Intimation for Notice Of Board Meeting To Consider The Un-AuditedFinancial Results Of The Company For The Quarter Ended 31 St December 2022
ADVIK LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (LODR) Regulations 2015 notice is hereby given that as per the requirements of Regulation 33 of the Securities and Exchange Board of India (LODR) Regulations 2015 a meeting of the Board of Directors of the company is scheduled to be held on Friday 03rd February 2023 at 12:00 P.M at the corporate office of the company at 703 Arunachal Building 19 Barakhambha Road Connaught Place New Delhi-110001 to inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended 31st December 2022 and to carry on any other business with the permission of the Board.
Sat, 21 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
With reference to the subject matter captioned above we are enclosing herewith the Certificateunder Regulation 74(5) of SEBI (Depository and Participant) Regulations 2018 for the quarterended 31st December 2022 received from M/s. MAS Services Private Limited the Registrar andShare Transfer Agent of our Company.
Thu, 12 Jan 2023
Statement Of Investor Complaints For The Quarter Ended 31St December 2022
As per the requirements of Regulation 13(3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 please find herein attached the Statement of Investor Complaints for the quarter ended 31st December 2022 for your kind perusal.

Technical Scans View Details >>

No Scans Found

Related Stocks View Details >>

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On MPS Pharmaa Ltd.

What is MPS Pharmaa share price?

Can I buy MPS Pharmaa shares now?

What is the Market Cap of MPS Pharmaa?

What are the key metrics to analyse MPS Pharmaa?

What is the 52 Week High and Low of MPS Pharmaa?